Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant in adolescents with chronic migraine
NL-OMON59986Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing Atogepant with Placebo (2 arms). Primary endpoint: Change from baseline in mean monthly migraine days across the 12-week treatment period. Started Jul 2025; status: recruiting.
02
Drugs
atogepant
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NL-OMON59986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59986.